Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
- PMID: 33798498
- PMCID: PMC8009607
- DOI: 10.1016/S0140-6736(21)00762-5
Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
Conflict of interest statement
SDØ received the 2020 Lundbeck Foundation Young Investigator Prize. All other authors declare no competing interests. The Department of Clinical Epidemiology is involved in studies with funding from various companies as research grants to (and administered by) Aarhus University. Author contributions and funding details are provided in the appendix.
Comment on
-
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots.BMJ. 2021 Mar 11;372:n699. doi: 10.1136/bmj.n699. BMJ. 2021. PMID: 33707182 No abstract available.
References
-
- Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699. - PubMed
-
- European Medicines Agency COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - update. March 11, 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-inve...
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
